Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, has appointed Caroline Stark Beer, MBA, as its Chief Business Officer. Caroline brings more than 20 years of experience in the life science industry. She was most recently CBO at Jnana Therapeutics until Jnana’s sale to Otsuka Pharmaceutical. Caroline led the team responsible for corporate and business...